Intravesical BCG Administration to Patients With Invasive Bladder Cancer

Stopped early · Not applicable

Conditions studied: Bladder Cancer

In brief

Patients with invasive bladder cancer will be given 3-6 treatments (based on treatment response) BCG intravesically followed by a cystectomy.

Key facts

Study ID

NCT02365207

Run by

The University of Texas Health Science Center at San Antonio

People needed

6

Starts

2013-11-01

Expected to finish

2019-04-25

Last updated by the study team

2019-11-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have suspected or known invasive (≥T1) bladder cancer
• Be able to give informed consent
• Be age 18 or older
• Not be in an immunosuppressed state (e.g. HIV+, use of chronic steroids >1 month)

You may not qualify if…

• Have non-invasive (<T1) bladder cancer
• Unable to give informed consent
• < 18 or older
• Is in an immunosuppressed state (e.g. HIV+, use of chronic steroids >1 month)

Where it is running

• MARC - The University of Texas Health Science Center — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.